Boiron (BOI) Stock Overview
Manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
BOI Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Boiron SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €26.00 |
| 52 Week High | €32.25 |
| 52 Week Low | €23.95 |
| Beta | 0.21 |
| 1 Month Change | -1.52% |
| 3 Month Change | -6.14% |
| 1 Year Change | 6.34% |
| 3 Year Change | -51.76% |
| 5 Year Change | -36.51% |
| Change since IPO | 462.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| BOI | FR Pharmaceuticals | FR Market | |
|---|---|---|---|
| 7D | -1.1% | -3.1% | -1.5% |
| 1Y | 6.3% | -4.2% | -1.5% |
Return vs Industry: BOI exceeded the French Pharmaceuticals industry which returned -4.2% over the past year.
Return vs Market: BOI exceeded the French Market which returned -1.5% over the past year.
Price Volatility
| BOI volatility | |
|---|---|
| BOI Average Weekly Movement | 2.3% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in FR Market | 8.9% |
| 10% least volatile stocks in FR Market | 2.1% |
Stable Share Price: BOI has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: BOI's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1932 | 2,499 | Pascal Houdayer | www.boiron.fr |
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices (in vitro diagnostics), dietary supplements, herbal remedies, cosmetics, and CBD-based products. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sedative PC Granules to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain.
Boiron SA Fundamentals Summary
| BOI fundamental statistics | |
|---|---|
| Market cap | €451.42m |
| Earnings (TTM) | €32.64m |
| Revenue (TTM) | €501.11m |
Is BOI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BOI income statement (TTM) | |
|---|---|
| Revenue | €501.11m |
| Cost of Revenue | €135.38m |
| Gross Profit | €365.73m |
| Other Expenses | €333.08m |
| Earnings | €32.64m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.88 |
| Gross Margin | 72.98% |
| Net Profit Margin | 6.51% |
| Debt/Equity Ratio | 3.1% |
How did BOI perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 14:59 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Boiron SA is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Guillaume Cuvillier | Gilbert Dupont |
| Stephanie Lefebvre | Gilbert Dupont |
| Christophe-Raphael Ganet | ODDO BHF Corporate & Markets |